000			02157nam a22003377a 4500
008			190314s20102010 xxu||||| |||| 00| 0 eng d
022			_a1939-4551
024			_a10.1097/WOX.0b013e3181d25eac [doi]
024			_a1939-4551-3-2-23 [pii]
024			_aPMC3651111 [pmc]
040			_aOvid MEDLINE(R)
099			_a24228852
245			_aSection 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast: Highlights of the Asthma Summit 2009: Beyond the Guidelines.
251			_aWorld Allergy Organization Journal. 3(2):23-30, 2010 Feb 15.
252			_aWorld Allergy Organiza. journal. 3(2):23-30, 2010 Feb 15.
253			_aThe World Allergy Organization journal
260			_c2010
260			_fFY2010
265			_sepublish
266			_d2019-03-14
520			_aExercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to as exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.
546			_aEnglish
650			_aPubMed-not-MEDLINE -- Not indexed
651			_aMedStar Washington Hospital Center
656			_aMedicine/Pulmonary-Critical Care
657			_aJournal Article
700			_aColice, Gene
790			_aCalhoun WJ, Colice G
856			_uhttps://dx.doi.org/10.1097/WOX.0b013e3181d25eac _zhttps://dx.doi.org/10.1097/WOX.0b013e3181d25eac
942			_cART _dArticle
999			_c4156 _d4156